Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Dec 27;2(12):442-6.
doi: 10.4254/wjh.v2.i12.442.

Development of osteomalacia in a post-liver transplant patient receiving adefovir dipivoxil

Masami Minemura  1 , Yoshiharu Tokimitsu, Kazuto Tajiri, Yasuhiro Nakayama, Kengo Kawai, Hiroshi Kudo, Katsuharu Hirano, Yoshinari Atarashi, Yutaka Yata, Satoshi Yasumura, Terumi Takahara, Toshiro Sugiyama
Affiliations

Development of osteomalacia in a post-liver transplant patient receiving adefovir dipivoxil

Masami Minemura et al. World J Hepatol. .

Abstract

We report the case of a patient treated with living donor-related liver transplantation who suffered from osteomalacia during adefovir dipivoxil (ADV)-containing antiviral therapy for lamivudine-resistant hepatitis B virus infection. The patient had generalized bone pain, with severe hypophosphatemia after 20 mo of ADV therapy. Radiographic studies demonstrated the presence of osteomalacia. The peak plasma ADV level was 38 ng/mL after administration of ADV at 10 mg/d. It was also found that ADV affected the metabolism of tacrolimus, a calcineurin-inhibitor, and caused an increase in the plasma levels of tacrolimus. The disability was reversed with the withdrawal of ADV and with mineral supplementation. ADV can cause an elevation of plasma tacrolimus levels, which may be associated with renal dysfunction. High levels of ADV and tacrolimus can cause nephrotoxicity and osteomalacia. This case highlights the importance of considering a diagnosis of osteomalacia in liver transplantation recipients treated with both ADV and tacrolimus.

Keywords: Adefovir dipivoxil; Hepatitis B virus; Living donor-related liver transplantation; Osteomalacia; Tacrolimus.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Whole body bone scintigraphy shows multiple foci of increased radiotracer uptake in the thoracic spine, the sacroiliac region, the rib cage, the shoulders, the knees, and the ankles.
Figure 2
Figure 2
Clinical course of the present case. After switching from ADV plus LAM to ETV, serum levels of P and ALP improved, and the patient’s bone pain also decreased dramatically. ADV: adefovir dipivoxil; LAM: lamivudine; ETV: entecavir hydrate; PSL: prednisolone; P: phosphate; APL: alkaline phosphatase; γ-GTP: γ-glutamyl transferase; LDLT: living donor-related liver transplantation.
See this image and copyright information in PMC

References

    1. Lok AS. Prevention of recurrent hepatitis B post-liver transplantation. Liver Transpl. 2002;8:S67–S73. - PubMed
    1. Shouval D, Samuel D. Hepatitis B immune globulin to prevent hepatitis B virus graft reinfection following liver transplantation: a concise review. Hepatology. 2000;32:1189–1195. - PubMed
    1. Karasu Z, Akyildiz M, Kilic M, Zeytunlu M, Aydin U, Tekin F, Yilmaz F, Ozacar T, Akarca U, Ersoz G, et al. Living donor liver transplantation for hepatitis B cirrhosis. J Gastroenterol Hepatol. 2007;22:2124–2129. - PubMed
    1. Ling R, Mutimer D, Ahmed M, Boxall EH, Elias E, Dusheiko GM, Harrison TJ. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine. Hepatology. 1996;24:711–713. - PubMed
    1. Tipples GA, Ma MM, Fischer KP, Bain VG, Kneteman NM, Tyrrell DL. Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology. 1996;24:714–717. - PubMed